Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis

To assess (1) comorbidities associated with and (2) treatment strategies for patients with adrenal incidentalomas and mild autonomous cortisol secretion (MACS; > 1.8 µg/dL (>50 nmol/L) cortisol level cut-off following the 1 mg dexamethasone suppression test). Systematic review and meta-analysi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of endocrinology 2023-10, Vol.189 (4), p.S88-S101
Hauptverfasser: Pelsma, Iris C M, Fassnacht, Martin, Tsagarakis, Stylianos, Terzolo, Massimo, Tabarin, Antoine, Sahdev, Anju, Newell-Price, John, Marina, Ljiljana, Lorenz, Kerstin, Bancos, Irina, Arlt, Wiebke, Dekkers, Olaf M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S101
container_issue 4
container_start_page S88
container_title European journal of endocrinology
container_volume 189
creator Pelsma, Iris C M
Fassnacht, Martin
Tsagarakis, Stylianos
Terzolo, Massimo
Tabarin, Antoine
Sahdev, Anju
Newell-Price, John
Marina, Ljiljana
Lorenz, Kerstin
Bancos, Irina
Arlt, Wiebke
Dekkers, Olaf M
description To assess (1) comorbidities associated with and (2) treatment strategies for patients with adrenal incidentalomas and mild autonomous cortisol secretion (MACS; > 1.8 µg/dL (>50 nmol/L) cortisol level cut-off following the 1 mg dexamethasone suppression test). Systematic review and meta-analysis. Seven databases were searched up to July 14, 2022. Eligible studies were (randomized) trials, cohort studies, and cross-sectional studies assessing comorbidities potentially attributable to cortisol excess or mortality in patients with adrenal incidentaloma with or without MACS or the effects of conservative or surgical management of MACS. Random-effects meta-analysis was performed to estimate pooled proportions (with 95% CIs). In 30 cross-sectional and 16 cohort studies (n = 17 156 patients in total), patients with MACS had a higher prevalence of diabetes (relative risk [RR] 1.44 [1.23-1.69]), hypertension (RR = 1.24 [1.16-1.32]), and dyslipidemia (RR = 1.23 [1.13-1.34]). All-cause mortality (adjusted for confounders) in patients with MACS, assessed in 4 studies (n = 5921), was increased (hazard ratio [HR] = 1.54 [1.27-1.81]). Nine observational studies (n = 856) and 2 randomized trials (n = 107) suggest an improvement in glucometabolic control (RR = 7.99 [2.95-21.90]), hypertension (RR = 8.75 [3.99-19.18]), and dyslipidemia (RR = 3.24 [1.19-8.82]) following adrenalectomy. The present systematic review and meta-analysis highlight the relevance of MACS, since both cardiometabolic morbidities and mortality appeared to have increased in patients with MACS compared to patients with non-functioning incidentalomas. However, due to heterogeneous definitions, various outcomes, selective reporting, and missing data, the reported pooled estimates need to be interpreted with caution. The small number of patients in randomized trials prevents any strong conclusion on the causality between MACS and these comorbidities.
doi_str_mv 10.1093/ejendo/lvad134
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2874263551</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2874263551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c335t-71fcac64e2c698c377d63f26ee9d7979b98b7dd3b5b07f79fcf69c243bf208f03</originalsourceid><addsrcrecordid>eNo9kE1LAzEQhoMotlavHiVHL1uTTTbZeJPiFxS8KHhbsskEU3Y3NUkr_feutnqaF-aZF-ZB6JKSOSWK3cAKBhtuuq22lPEjNKVcqkLU7P0YTUlNeMEFZxN0ltKKEDpmcoomTNZjrqopyovQh9h667OHhP2Ae99ZrDc5DONmk7AJMfsUOpzARMg-DFgPFucPwOAcmIyDwzmCzj0M-RanXcrQ6-wNjrD18PWL95B1oQfd7ZJP5-jE6S7BxWHO0NvD_eviqVi-PD4v7paFYazKhaTOaCM4lEao2jAprWCuFADKSiVVq-pWWsvaqiXSSeWME8qUnLWuJLUjbIau973rGD43kHLT-2Sg6_QA42tNWUteClZVdETne9TEkFIE16yj73XcNZQ0P6abvenmYHo8uDp0b9oe7D_-p5Z9AwH4f3M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2874263551</pqid></control><display><type>article</type><title>Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Pelsma, Iris C M ; Fassnacht, Martin ; Tsagarakis, Stylianos ; Terzolo, Massimo ; Tabarin, Antoine ; Sahdev, Anju ; Newell-Price, John ; Marina, Ljiljana ; Lorenz, Kerstin ; Bancos, Irina ; Arlt, Wiebke ; Dekkers, Olaf M</creator><creatorcontrib>Pelsma, Iris C M ; Fassnacht, Martin ; Tsagarakis, Stylianos ; Terzolo, Massimo ; Tabarin, Antoine ; Sahdev, Anju ; Newell-Price, John ; Marina, Ljiljana ; Lorenz, Kerstin ; Bancos, Irina ; Arlt, Wiebke ; Dekkers, Olaf M</creatorcontrib><description>To assess (1) comorbidities associated with and (2) treatment strategies for patients with adrenal incidentalomas and mild autonomous cortisol secretion (MACS; &gt; 1.8 µg/dL (&gt;50 nmol/L) cortisol level cut-off following the 1 mg dexamethasone suppression test). Systematic review and meta-analysis. Seven databases were searched up to July 14, 2022. Eligible studies were (randomized) trials, cohort studies, and cross-sectional studies assessing comorbidities potentially attributable to cortisol excess or mortality in patients with adrenal incidentaloma with or without MACS or the effects of conservative or surgical management of MACS. Random-effects meta-analysis was performed to estimate pooled proportions (with 95% CIs). In 30 cross-sectional and 16 cohort studies (n = 17 156 patients in total), patients with MACS had a higher prevalence of diabetes (relative risk [RR] 1.44 [1.23-1.69]), hypertension (RR = 1.24 [1.16-1.32]), and dyslipidemia (RR = 1.23 [1.13-1.34]). All-cause mortality (adjusted for confounders) in patients with MACS, assessed in 4 studies (n = 5921), was increased (hazard ratio [HR] = 1.54 [1.27-1.81]). Nine observational studies (n = 856) and 2 randomized trials (n = 107) suggest an improvement in glucometabolic control (RR = 7.99 [2.95-21.90]), hypertension (RR = 8.75 [3.99-19.18]), and dyslipidemia (RR = 3.24 [1.19-8.82]) following adrenalectomy. The present systematic review and meta-analysis highlight the relevance of MACS, since both cardiometabolic morbidities and mortality appeared to have increased in patients with MACS compared to patients with non-functioning incidentalomas. However, due to heterogeneous definitions, various outcomes, selective reporting, and missing data, the reported pooled estimates need to be interpreted with caution. The small number of patients in randomized trials prevents any strong conclusion on the causality between MACS and these comorbidities.</description><identifier>ISSN: 0804-4643</identifier><identifier>EISSN: 1479-683X</identifier><identifier>DOI: 10.1093/ejendo/lvad134</identifier><identifier>PMID: 37801655</identifier><language>eng</language><publisher>England</publisher><subject>Adrenal Gland Neoplasms - complications ; Cross-Sectional Studies ; Dyslipidemias - complications ; Humans ; Hydrocortisone ; Hypertension - complications</subject><ispartof>European journal of endocrinology, 2023-10, Vol.189 (4), p.S88-S101</ispartof><rights>The Author(s) 2023. Published by Oxford University Press on behalf of European Society of Endocrinology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c335t-71fcac64e2c698c377d63f26ee9d7979b98b7dd3b5b07f79fcf69c243bf208f03</citedby><cites>FETCH-LOGICAL-c335t-71fcac64e2c698c377d63f26ee9d7979b98b7dd3b5b07f79fcf69c243bf208f03</cites><orcidid>0000-0003-1959-8738 ; 0000-0003-4956-4037 ; 0000-0003-1231-3306 ; 0000-0001-6170-6398 ; 0000-0001-9332-2524 ; 0000-0001-5106-9719 ; 0000-0002-0835-5493</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37801655$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pelsma, Iris C M</creatorcontrib><creatorcontrib>Fassnacht, Martin</creatorcontrib><creatorcontrib>Tsagarakis, Stylianos</creatorcontrib><creatorcontrib>Terzolo, Massimo</creatorcontrib><creatorcontrib>Tabarin, Antoine</creatorcontrib><creatorcontrib>Sahdev, Anju</creatorcontrib><creatorcontrib>Newell-Price, John</creatorcontrib><creatorcontrib>Marina, Ljiljana</creatorcontrib><creatorcontrib>Lorenz, Kerstin</creatorcontrib><creatorcontrib>Bancos, Irina</creatorcontrib><creatorcontrib>Arlt, Wiebke</creatorcontrib><creatorcontrib>Dekkers, Olaf M</creatorcontrib><title>Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis</title><title>European journal of endocrinology</title><addtitle>Eur J Endocrinol</addtitle><description>To assess (1) comorbidities associated with and (2) treatment strategies for patients with adrenal incidentalomas and mild autonomous cortisol secretion (MACS; &gt; 1.8 µg/dL (&gt;50 nmol/L) cortisol level cut-off following the 1 mg dexamethasone suppression test). Systematic review and meta-analysis. Seven databases were searched up to July 14, 2022. Eligible studies were (randomized) trials, cohort studies, and cross-sectional studies assessing comorbidities potentially attributable to cortisol excess or mortality in patients with adrenal incidentaloma with or without MACS or the effects of conservative or surgical management of MACS. Random-effects meta-analysis was performed to estimate pooled proportions (with 95% CIs). In 30 cross-sectional and 16 cohort studies (n = 17 156 patients in total), patients with MACS had a higher prevalence of diabetes (relative risk [RR] 1.44 [1.23-1.69]), hypertension (RR = 1.24 [1.16-1.32]), and dyslipidemia (RR = 1.23 [1.13-1.34]). All-cause mortality (adjusted for confounders) in patients with MACS, assessed in 4 studies (n = 5921), was increased (hazard ratio [HR] = 1.54 [1.27-1.81]). Nine observational studies (n = 856) and 2 randomized trials (n = 107) suggest an improvement in glucometabolic control (RR = 7.99 [2.95-21.90]), hypertension (RR = 8.75 [3.99-19.18]), and dyslipidemia (RR = 3.24 [1.19-8.82]) following adrenalectomy. The present systematic review and meta-analysis highlight the relevance of MACS, since both cardiometabolic morbidities and mortality appeared to have increased in patients with MACS compared to patients with non-functioning incidentalomas. However, due to heterogeneous definitions, various outcomes, selective reporting, and missing data, the reported pooled estimates need to be interpreted with caution. The small number of patients in randomized trials prevents any strong conclusion on the causality between MACS and these comorbidities.</description><subject>Adrenal Gland Neoplasms - complications</subject><subject>Cross-Sectional Studies</subject><subject>Dyslipidemias - complications</subject><subject>Humans</subject><subject>Hydrocortisone</subject><subject>Hypertension - complications</subject><issn>0804-4643</issn><issn>1479-683X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kE1LAzEQhoMotlavHiVHL1uTTTbZeJPiFxS8KHhbsskEU3Y3NUkr_feutnqaF-aZF-ZB6JKSOSWK3cAKBhtuuq22lPEjNKVcqkLU7P0YTUlNeMEFZxN0ltKKEDpmcoomTNZjrqopyovQh9h667OHhP2Ae99ZrDc5DONmk7AJMfsUOpzARMg-DFgPFucPwOAcmIyDwzmCzj0M-RanXcrQ6-wNjrD18PWL95B1oQfd7ZJP5-jE6S7BxWHO0NvD_eviqVi-PD4v7paFYazKhaTOaCM4lEao2jAprWCuFADKSiVVq-pWWsvaqiXSSeWME8qUnLWuJLUjbIau973rGD43kHLT-2Sg6_QA42tNWUteClZVdETne9TEkFIE16yj73XcNZQ0P6abvenmYHo8uDp0b9oe7D_-p5Z9AwH4f3M</recordid><startdate>20231017</startdate><enddate>20231017</enddate><creator>Pelsma, Iris C M</creator><creator>Fassnacht, Martin</creator><creator>Tsagarakis, Stylianos</creator><creator>Terzolo, Massimo</creator><creator>Tabarin, Antoine</creator><creator>Sahdev, Anju</creator><creator>Newell-Price, John</creator><creator>Marina, Ljiljana</creator><creator>Lorenz, Kerstin</creator><creator>Bancos, Irina</creator><creator>Arlt, Wiebke</creator><creator>Dekkers, Olaf M</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1959-8738</orcidid><orcidid>https://orcid.org/0000-0003-4956-4037</orcidid><orcidid>https://orcid.org/0000-0003-1231-3306</orcidid><orcidid>https://orcid.org/0000-0001-6170-6398</orcidid><orcidid>https://orcid.org/0000-0001-9332-2524</orcidid><orcidid>https://orcid.org/0000-0001-5106-9719</orcidid><orcidid>https://orcid.org/0000-0002-0835-5493</orcidid></search><sort><creationdate>20231017</creationdate><title>Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis</title><author>Pelsma, Iris C M ; Fassnacht, Martin ; Tsagarakis, Stylianos ; Terzolo, Massimo ; Tabarin, Antoine ; Sahdev, Anju ; Newell-Price, John ; Marina, Ljiljana ; Lorenz, Kerstin ; Bancos, Irina ; Arlt, Wiebke ; Dekkers, Olaf M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c335t-71fcac64e2c698c377d63f26ee9d7979b98b7dd3b5b07f79fcf69c243bf208f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adrenal Gland Neoplasms - complications</topic><topic>Cross-Sectional Studies</topic><topic>Dyslipidemias - complications</topic><topic>Humans</topic><topic>Hydrocortisone</topic><topic>Hypertension - complications</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pelsma, Iris C M</creatorcontrib><creatorcontrib>Fassnacht, Martin</creatorcontrib><creatorcontrib>Tsagarakis, Stylianos</creatorcontrib><creatorcontrib>Terzolo, Massimo</creatorcontrib><creatorcontrib>Tabarin, Antoine</creatorcontrib><creatorcontrib>Sahdev, Anju</creatorcontrib><creatorcontrib>Newell-Price, John</creatorcontrib><creatorcontrib>Marina, Ljiljana</creatorcontrib><creatorcontrib>Lorenz, Kerstin</creatorcontrib><creatorcontrib>Bancos, Irina</creatorcontrib><creatorcontrib>Arlt, Wiebke</creatorcontrib><creatorcontrib>Dekkers, Olaf M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pelsma, Iris C M</au><au>Fassnacht, Martin</au><au>Tsagarakis, Stylianos</au><au>Terzolo, Massimo</au><au>Tabarin, Antoine</au><au>Sahdev, Anju</au><au>Newell-Price, John</au><au>Marina, Ljiljana</au><au>Lorenz, Kerstin</au><au>Bancos, Irina</au><au>Arlt, Wiebke</au><au>Dekkers, Olaf M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis</atitle><jtitle>European journal of endocrinology</jtitle><addtitle>Eur J Endocrinol</addtitle><date>2023-10-17</date><risdate>2023</risdate><volume>189</volume><issue>4</issue><spage>S88</spage><epage>S101</epage><pages>S88-S101</pages><issn>0804-4643</issn><eissn>1479-683X</eissn><abstract>To assess (1) comorbidities associated with and (2) treatment strategies for patients with adrenal incidentalomas and mild autonomous cortisol secretion (MACS; &gt; 1.8 µg/dL (&gt;50 nmol/L) cortisol level cut-off following the 1 mg dexamethasone suppression test). Systematic review and meta-analysis. Seven databases were searched up to July 14, 2022. Eligible studies were (randomized) trials, cohort studies, and cross-sectional studies assessing comorbidities potentially attributable to cortisol excess or mortality in patients with adrenal incidentaloma with or without MACS or the effects of conservative or surgical management of MACS. Random-effects meta-analysis was performed to estimate pooled proportions (with 95% CIs). In 30 cross-sectional and 16 cohort studies (n = 17 156 patients in total), patients with MACS had a higher prevalence of diabetes (relative risk [RR] 1.44 [1.23-1.69]), hypertension (RR = 1.24 [1.16-1.32]), and dyslipidemia (RR = 1.23 [1.13-1.34]). All-cause mortality (adjusted for confounders) in patients with MACS, assessed in 4 studies (n = 5921), was increased (hazard ratio [HR] = 1.54 [1.27-1.81]). Nine observational studies (n = 856) and 2 randomized trials (n = 107) suggest an improvement in glucometabolic control (RR = 7.99 [2.95-21.90]), hypertension (RR = 8.75 [3.99-19.18]), and dyslipidemia (RR = 3.24 [1.19-8.82]) following adrenalectomy. The present systematic review and meta-analysis highlight the relevance of MACS, since both cardiometabolic morbidities and mortality appeared to have increased in patients with MACS compared to patients with non-functioning incidentalomas. However, due to heterogeneous definitions, various outcomes, selective reporting, and missing data, the reported pooled estimates need to be interpreted with caution. The small number of patients in randomized trials prevents any strong conclusion on the causality between MACS and these comorbidities.</abstract><cop>England</cop><pmid>37801655</pmid><doi>10.1093/ejendo/lvad134</doi><orcidid>https://orcid.org/0000-0003-1959-8738</orcidid><orcidid>https://orcid.org/0000-0003-4956-4037</orcidid><orcidid>https://orcid.org/0000-0003-1231-3306</orcidid><orcidid>https://orcid.org/0000-0001-6170-6398</orcidid><orcidid>https://orcid.org/0000-0001-9332-2524</orcidid><orcidid>https://orcid.org/0000-0001-5106-9719</orcidid><orcidid>https://orcid.org/0000-0002-0835-5493</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0804-4643
ispartof European journal of endocrinology, 2023-10, Vol.189 (4), p.S88-S101
issn 0804-4643
1479-683X
language eng
recordid cdi_proquest_miscellaneous_2874263551
source MEDLINE; Oxford University Press Journals All Titles (1996-Current)
subjects Adrenal Gland Neoplasms - complications
Cross-Sectional Studies
Dyslipidemias - complications
Humans
Hydrocortisone
Hypertension - complications
title Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T18%3A21%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comorbidities%20in%20mild%20autonomous%20cortisol%20secretion%20and%20the%20effect%20of%20treatment:%20systematic%20review%20and%20meta-analysis&rft.jtitle=European%20journal%20of%20endocrinology&rft.au=Pelsma,%20Iris%20C%20M&rft.date=2023-10-17&rft.volume=189&rft.issue=4&rft.spage=S88&rft.epage=S101&rft.pages=S88-S101&rft.issn=0804-4643&rft.eissn=1479-683X&rft_id=info:doi/10.1093/ejendo/lvad134&rft_dat=%3Cproquest_cross%3E2874263551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2874263551&rft_id=info:pmid/37801655&rfr_iscdi=true